https://www.selleckchem.com/TGF-beta.html
Each year, the proportion of thyroid cancer patients presenting with low-risk disease is increasing. The shift in the landscape of thyroid cancer presentation is forcing clinicians to re-evaluate not only management, but surveillance paradigms. During the follow-up, patients are stratified considering their response to treatment, and classified into one of the following response categories excellent biochemical incomplete, structural incomplete, or indeterminate. These categories reflect a real-time prognosis and thereby substantially influence
Like
Comment
Share
